A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-hodgkin lymphoma, multiple myeloma, or castleman disease

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3659-3670

  Kurzrock, Razelle ^a   Voorhees, Peter M ^b   Casper, Corey ^c   Furman, Richard R ^d   Fayad, Luis ^a   Lonial, Sagar ^f   Borghaei, Hossein ^g   Jagannath, Sundar ^e   Sokol, Lubomir ⁱ   Usmani, Saad Z ^j   Van De Velde, Helgi ^h   Qin, Xiang ^h   Puchalski, Thomas A ^h   Hall, Brett ^h   Reddy, Manjula ^h   Qi, Ming ^h   Van Rhee, Frits ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j Myeloma Institute for Research and Therapy   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYPERTENSIVE AGENT; INTERLEUKIN 6; SILTUXIMAB; ANTINEOPLASTIC AGENT; HEMOGLOBIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELLULITIS; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EAR INFECTION; ENZYME REPRESSION; FEMALE; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOGENICITY; LARGE CELL LYMPHOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; CANCER STAGING; CLINICAL TRIAL; GIANT LYMPH NODE HYPERPLASIA; LYMPHOMA, B-CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HEMOGLOBINS; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 84879849025     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3349     Document Type: Article

References (36)

1. Haddad E, Paczesny S, Leblond V, Seigneurin JM, Stern M, Achkar A, et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001;97:1590-7.
2. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 andits receptor in cancer: implications for translational therapeutics. Cancer 2007;110:1911-28. (Pubitemid 350036849)
3. Sansone P, Bromberg J. Targeting the interleukin-6/jak/stat pathway in human malignancies. J Clin Oncol 2012;30:1005-14.
4. Rawstron AC, Fenton JAL, Ashcroft J, English A, Jones RA, Richards SJ, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000;96:3880-6.
5. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993;53:2118-22. (Pubitemid 23145736)
6. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995;13:575-82.
7. Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997;127:186-94. (Pubitemid 27332536)
8. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease. Am J Med 1997;102:21-8. (Pubitemid 27089983)
9. Kurzrock R. Cytokine deregulation in hematological malignancies: clinical and biological implications. Clin Cancer Res 1997;3:2581-4. (Pubitemid 28133109)
10. Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 1998;30:563-71. (Pubitemid 28393690)
11. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995;85:765-71.
12. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7. (Pubitemid 19227448)
13. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61. (Pubitemid 30017224)
14. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti -interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32. (Pubitemid 41510733)
15. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65. (Pubitemid 37323267)
16. van Zaanen HCT, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I doseescalating study. Br J Haematol 1998;102:783-90. (Pubitemid 28387063)
17. Van Zaanen HCT, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, Van Oers MH. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130. Leuk Lymphoma 1998;31:551-8. (Pubitemid 29050596)
18. Puchalski T, Prabhakar U, Jiao Q, Berns B, DavisHM. Pharmacokinetic and pharmacodynamic modeling of an anti -interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010;16:1652-61.
19. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010;28:3701-8.
20. Cheson BD, Horning SJ, Coif fier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244-53. (Pubitemid 29162950)
21. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7. (Pubitemid 26189840)
22. Weber D, Treon SP, Emmanouilides C, Branagan AR, Byrd JC, Blade J, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:127-31.
23. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23. (Pubitemid 28435189)
24. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 1998;31:351-7. (Pubitemid 29033956)
25. Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010;28:2538-43.
26. Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008;14:3262-7.
27. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010;116:3627-34.
28. Schipperus M, Rijnbeek B, Reddy M, Qin X, Cornfeld MJ. CNTO328 (anti-IL-6mAb) treatment is associated with an increase in hemoglobin (Hb) and decrease in hepcidin levels in renal cell carcinoma (RCC). Blood 2009;114:(suppl; abstr 4045).
29. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
30. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-58.
31. Kassem M, Khosla S, Spelsberg TC, Riggs BL. Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. J Clin Endocrinol Metab 1996;81:513-8. (Pubitemid 26055656)
32. Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, et al. The clinical spectrum of Castleman's disease. Am J Hematol 2012;87:997-1002.
33. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease:a systematic review of 404 published cases. Ann Surg 2012;255:677-84.
34. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004;79:867-74. (Pubitemid 38879952)
35. van Rhee F, Capra M, Wong R, Vermeulen J, Safer K, Todorovic M, et al. Recruitment in a randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in patients with multicentric Castleman's disease. J Clin Oncol 30, 2012 (suppl; abstr TPS8117).
36. Li LY, Kurzrock R, van Rhee F, Qin X, Reddy M, Qi M, et al. Population pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody, siltuximab (CNTO 328), in patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease. [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Washington, DC: ASH; 2012. Abstract 1365.